Need Help? Chat Now With a Live Representative!

Applied Clinical Trials: "Improving Information Exchange in Clinical Trials"

Applied Clinical Trials: "Improving Information Exchange in Clinical Trials"

Applied Clinical Trials: "Improving Information Exchange in Clinical Trials"

September 16, 2019

Hunter Walker, ARG CTO, recently provided ideas for a piece in Applied Clinical Trials by Jason Methia, entitled "Improving Information Exchange in Clinical Trials."

Speaking on a macro level, Hunter summarized the state of the industry in terms of information exchange:  "Looking at the medical and electronic health record (EHR) world that is part of healthcare today, a lot of these companies developed big systems that have essentially created silos among stakeholders. After entering data into the system, the user has no easy means for data export, migration, or exchange. This dramatically impacts the communications between the site and CRO."

Also appearing the piece, facilitated by ARG partner Veeva Systems:

  • Doug Schantz, executive director, development operations, AstraZeneca
  • Ken Getz, MBA, director of sponsored programs and associate research professor at Tufts Center for Drug Development
  • Bree Burks, RN, MSN, CCRP, director at Vanderbilt Institute for Clinical and Translational research (VICTR)
  • Jeff Kingsley, DO, MBA, CPI, FACRP, founder and CEO at IACT Health

Please find the entire article here.

Breaking Ground in Medicine: Our Role in the Approval of Bivigam by ADMA Biologics

Breaking Ground in Medicine: Our Role in the Approval of Bivigam by ADMA Biologics

Since 2004, ARG has been working in the immunology space, using our individualized approach to optimize the likelihood of successful […]

March 8, 2024
ARG and Humacyte Collaborate on Human Acellular Vessel (HAV) Program Advancements in Vascular Trauma

ARG and Humacyte Collaborate on Human Acellular Vessel (HAV) Program Advancements in Vascular Trauma

CHARLOTTESVILLE, VIRGINIA – ARG (Atlantic Research Group) proudly announces its ongoing collaboration with Humacyte, a leading biotechnology company, on the […]

February 23, 2024
Revolutionizing Treatment: Our Contribution to Humacyte’s Latest Innovation

Revolutionizing Treatment: Our Contribution to Humacyte’s Latest Innovation

In 2014, ARG began working with Humacyte on their Human Acellular Vessel (HAV) interposition graft program, which included three separate […]

February 7, 2024
GO TO TOP